Managing Shuffling Gait Associated with Haloperidol Use

Introduction to Management

• The American Academy of Family Physicians recommends switching to an atypical antipsychotic agent such as risperidone, olanzapine, or quetiapine when a patient develops a shuffling gait due to haloperidol, as these medications have significantly lower risk of extrapyramidal symptoms compared to typical antipsychotics like haloperidol 1, 2

Understanding the Problem

• Shuffling gait is a manifestation of extrapyramidal symptoms (EPS), which are common side effects of typical antipsychotics like haloperidol, affecting patients taking these medications 1, 2

Management Algorithm

• The American Academy of Family Physicians suggests replacing haloperidol with an atypical antipsychotic agent, such as risperidone (starting at 0.25 mg daily, maximum 2-3 mg daily), olanzapine (starting at 2.5 mg daily, maximum 10 mg daily), or quetiapine (starting at 12.5 mg twice daily, maximum 200 mg twice daily) 1, 2, 3
• If switching medications is not immediately possible, the Journal of the American Academy of Child and Adolescent Psychiatry recommends decreasing the dose of haloperidol, while monitoring closely for return of psychotic symptoms 1, 4

Special Considerations

• Regular assessment for worsening of EPS symptoms is essential, as they can progress to irreversible tardive dyskinesia with prolonged use, with elderly patients being at higher risk 1, 2
• The American Academy of Family Physicians guidelines strongly recommend atypical antipsychotics over typical ones like haloperidol specifically due to the lower risk of EPS, with a relative risk of 5.48 for parkinsonism 1, 2, 5

Common Pitfalls to Avoid

• The Journal of the American Academy of Child and Adolescent Psychiatry advises against misattributing all gait disturbances in patients on haloperidol to the medication, and considering other neurological causes 4
• The American Academy of Family Physicians and the Journal of the National Comprehensive Cancer Network recommend avoiding polypharmacy by not adding medications to treat side effects rather than addressing the primary cause, which can lead to cascading adverse effects 1, 5
• After switching medications, it is crucial to continue monitoring for both resolution of EPS and control of the original symptoms, as recommended by the American Academy of Family Physicians and the Journal of the National Comprehensive Cancer Network 1, 5